Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Kadcyla and neratinib for interception of HER2-positive breast cancer with molecular residual disease

Phase 2 trial whose registry primary outcome is clearance of ctDNA, measured with the RaDaR assay, after neratinib is added to trastuzumab emtansine in people with detectable MRD. ClinicalTrials.gov lists the study as recruiting.

University Health Network, Toronto